Genetic basis of atherosclerosis: part II: clinical implications.
Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, USA. jlusis@mednet.ucla.edu.
Aldons J
AJ
Lusis
Alan M
AM
Fogelman
Gregg C
GC
Fonarow
D000818:Animals; D016632:Apolipoprotein A-I / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics / Q000502:physiology; D001161:Arteriosclerosis / Q000235:genetics* / Q000517:prevention & control / Q000628:therapy; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000517:prevention & control; D004353:Drug Evaluation, Preclinical; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D015289:Leukotrienes / Q000378:metabolism; D008019:Life Style; D008075:Lipoproteins, HDL / Q000097:blood / Q000235:genetics; D008077:Lipoproteins, LDL / Q000097:blood / Q000235:genetics; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D015337:Multicenter Studies as Topic; D019683:Penetrance; D010597:Pharmacogenetics; D010743:Phospholipids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012306:Risk
D016632:Apolipoprotein A-I; D015289:Leukotrienes; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010743:Phospholipids; D011994:Recombinant Proteins; C080631:apolipoprotein A-I Milano; D001094:Arachidonate 5-Lipoxygenase; D042965:Methylenetetrahydrofolate Reductase (NADPH2)